104 related articles for article (PubMed ID: 23869521)
1. Cereblon expression in multiple myeloma: not ready for prime time - response to Lodé et al.
Zojer N; Heintel D; Palumbo A; Ludwig H
Br J Haematol; 2013 Oct; 163(2):285-6. PubMed ID: 23869521
[No Abstract] [Full Text] [Related]
2. Cereblon expression in multiple myeloma: not ready for prime time.
Lodé L; Amiot M; Maiga S; Touzeau C; Menard A; Magrangeas F; Minvielle S; Pellat-Deceunynck C; Bene MC; Moreau P
Br J Haematol; 2013 Oct; 163(2):282-4. PubMed ID: 23862718
[No Abstract] [Full Text] [Related]
3. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
4. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
Ren Y; Wang M; Couto S; Hansel DE; Miller K; Lopez-Girona A; Bjorklund CC; Gandhi AK; Thakurta A; Chopra R; Breider M
Appl Immunohistochem Mol Morphol; 2016; 24(10):695-702. PubMed ID: 26186254
[TBL] [Abstract][Full Text] [Related]
5. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention for smoldering multiple myeloma: not ready for prime time.
Gertz MA
Leuk Lymphoma; 2013 Oct; 54(10):2331-2. PubMed ID: 23540344
[No Abstract] [Full Text] [Related]
7. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
8. IMiDs: Not for the CRBN weak.
Pearse RN
Leuk Res; 2014 Jan; 38(1):21-2. PubMed ID: 24239176
[No Abstract] [Full Text] [Related]
9. [Clear cell myeloma: report of a case].
Xu H; Li J; Yang S
Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):196-7. PubMed ID: 24842022
[No Abstract] [Full Text] [Related]
10. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
11. Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.
Ise M; Matsubayashi K; Tsujimura H; Kumagai K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e59-64. PubMed ID: 26997107
[No Abstract] [Full Text] [Related]
12. Novel combination approaches for myeloma.
Lonial S; Nooka AK
Hematology Am Soc Hematol Educ Program; 2015; 2015():286-93. PubMed ID: 26637735
[No Abstract] [Full Text] [Related]
13. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D; Luczak M; Wrobel T; Usnarska-Zubkiewicz L; Brzezniakiewicz K; Jamroziak K; Giannopoulos K; Przybylowicz-Chalecka A; Ratajczak B; Czerwinska-Rybak J; Nowicki A; Joks M; Czechowska E; Zawartko M; Szczepaniak T; Grzasko N; Morawska M; Bochenek M; Kubicki T; Morawska M; Tusznio K; Jakubowiak A; Komarnicki MA
Oncotarget; 2016 Aug; 7(35):56726-56736. PubMed ID: 27527861
[TBL] [Abstract][Full Text] [Related]
14. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
15. Cereblon: A Protein Crucial to the Multiple Functions of Immunomodulatory Drugs as well as Cell Metabolism and Disease Generation.
Shi Q; Chen L
J Immunol Res; 2017; 2017():9130608. PubMed ID: 28894755
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib, thalidomide and dexamethasone versus bortezomib, cyclophosphamide and dexamethasone as induction therapy prior to ASCT in multiple myeloma - response to Moreau et al.
Leiba M; Avigdor A
Br J Haematol; 2015 Feb; 168(4):604-5. PubMed ID: 25252030
[No Abstract] [Full Text] [Related]
17. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.
Samo AA; Li J; Zhou M; Sun Y; Yang Y; Zhang Y; Li J; van Duin M; Lu X; Fan X
Genes Chromosomes Cancer; 2018 Aug; 57(8):420-429. PubMed ID: 29696703
[TBL] [Abstract][Full Text] [Related]
18. Induction of integrin beta1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma.
Kurata M; Nakagawa Y; Yamamoto K; Suzuki K; Kitagawa M
Am J Hematol; 2008 Sep; 83(9):755-7. PubMed ID: 18615555
[No Abstract] [Full Text] [Related]
19. [Multiple myeloma: past, present and future--editorial].
Ke XY; Wang YF; Yang YH; Wang LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):231-9. PubMed ID: 18426640
[TBL] [Abstract][Full Text] [Related]
20. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients.
Franssen LE; Nijhof IS; Couto S; Levin MD; Bos GMJ; Broijl A; Klein SK; Ren Y; Wang M; Koene HR; Bloem AC; Beeker A; Faber LM; van der Spek E; Raymakers R; Leguit RJ; Sonneveld P; Zweegman S; Lokhorst H; Mutis T; Thakurta A; Qian X; van de Donk NWCJ
Haematologica; 2018 Aug; 103(8):e368-e371. PubMed ID: 29545338
[No Abstract] [Full Text] [Related]
[Next] [New Search]
